Achaogen (NASDAQ:AKAO) major shareholder Robert W. Duggan purchased 119,700 shares of the company’s stock in a transaction on Thursday, April 19th. The shares were purchased at an average cost of $12.76 per share, for a total transaction of $1,527,372.00. Following the completion of the transaction, the insider now directly owns 6,602,269 shares of the company’s stock, valued at approximately $84,244,952.44. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
NASDAQ:AKAO opened at $13.12 on Wednesday. Achaogen has a one year low of $9.83 and a one year high of $27.49. The firm has a market capitalization of $598.65, a price-to-earnings ratio of -4.14 and a beta of 1.02. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.83 and a current ratio of 4.83.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.21). Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%. The business had revenue of $1.87 million during the quarter, compared to analyst estimates of $1.18 million. analysts predict that Achaogen will post -3.48 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new position in shares of Achaogen in the fourth quarter valued at about $151,000. Ellington Management Group LLC acquired a new position in shares of Achaogen in the fourth quarter valued at about $177,000. Clear Harbor Asset Management LLC acquired a new position in shares of Achaogen in the fourth quarter valued at about $177,000. Tower Research Capital LLC TRC grew its stake in shares of Achaogen by 375.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after acquiring an additional 14,725 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Achaogen in the fourth quarter valued at about $260,000. Institutional investors and hedge funds own 77.41% of the company’s stock.
Several equities analysts have commented on AKAO shares. Guggenheim reiterated a “buy” rating and issued a $14.00 price objective on shares of Achaogen in a report on Wednesday, January 10th. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price objective (down from $29.00) on shares of Achaogen in a report on Wednesday, February 28th. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. BidaskClub upgraded shares of Achaogen from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Stifel Nicolaus decreased their price objective on shares of Achaogen from $27.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.56.
TRADEMARK VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/25/achaogen-akao-major-shareholder-buys-1527372-00-in-stock.html.
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.